Precise robotic treatment as individual as every patient
Why Prostate SBRT With The CyberKnife® System Is Beneficial For Your Patients And Your Practice.
Prostate cancer is an expensive illness. It’s predicted that the number of prostate cancer cases will increase by approximately 32% over the next 22 years1. This can be costly for you and your patients.
Here we will share with you how Accuray helps you fight against prostate cancer by providing you with precise and personalized cancer treatment for every patient. You can read about clinical studies and watch testimonials from well-known radiation oncologists below.
If you would like more information from Accuray, please fill in this form.
Confidently delivering effective treatments with minimal side effects.
Making personalized treatments practical for every patient.
Ensuring fewer treatments and a faster return to daily life.
Precise Robotic Treatment As Individual As Every Patient.
The premier solution for low and intermediate risk prostate cancer. The CyberKnife System is designed to streamline and optimize Stereotactic Body Radiation Therapy (SBRT) to benefit your practice and your patients.
Watch our new CyberKnife prostate cancer animation.
Connect with a sales representative.
These studies, conducted at academic and community medical centers across the United States, provide robust clinical data supporting the safety and efficacy of CyberKnife Stereotactic Body Radiotherapy (SBRT) for patients with low – and intermediate-risk prostate cancer.
Clinical article published in the February edition of the ASTRO Red Journal provides efficacy and toxicity outcomes of men with recurrent prostate cancer treated with The CyberKnife System after failure of previous radiation therapy.
Two large prospective, multi-institutional and CyberKnife system only clinical studies report excellent clinical outcomes at five years post-treatment.
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints.
Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
Hear It for Yourself
Hear Dr. Donald B. Fuller, M.D., Radiation Oncologist, who was an early adopter of the CyberKnife System at the Genesis Healthcare Partners in San Diego.
Hear Dr. Robert M. Meier, M.D., Medical Director of Radiation Oncology at the Radiosurgery Center at Swedish Medical Center in Seattle.
1) Data source Globocan 2018 and http://gco.iarc.fr/
We Are In This Fight Together
“Our study treated over 300 prostate cancer patients across 21 centers throughout the United States. The CyberKnife’s unique architecture tracks and automatically corrects for prostate motion, delivering radiation with sub-millimeter accuracy. This exceptional precision allowed us to give a more effective dose of radiotherapy, which translated into superior cancer control. Since we were able to avoid the healthy tissues which lie immediately adjacent to the prostate, side effects were uncommon,” said Robert M. Meier, MD, medical director of the Swedish Radiosurgery Center in Seattle and lead investigator of the study published in the International Journal of Radiation Oncology*Biology*Physics.
Donald B. Fuller, MD, radiation oncologist at Genesis Healthcare Partners in San Diego and lead investigator of the European Urology Oncology study, “We evaluated an SBRT dosing regimen designed to emulate successful high dose rate (HDR) brachytherapy plans and delivered in four visits. Study outcomes demonstrate that CyberKnife prostate SBRT is safe and effective for low- and intermediate-risk prostate cancer patients, producing a lower PSA nadir level than previously reported with other external radiotherapy techniques (< 0.1 ng/mL at 4 years and beyond), with minimal impact on quality of life during and after treatment. Of note, our treatment plans required steep dose fall-off from high-dose regions close to the bladder, urethra and rectum that would be difficult to deliver safely without the unique continual image-guidance and automatic correction of the beam aim made possible by the CyberKnife System.”
Stereotactic Body Radiation Therapy for Unfavorable Intermediate- and High-Risk Prostate Cancer: 3-Year Outcomes of a Phase II Trial.
At the recent ASTRO annual meeting Dr. Macias, from Spain, reported on his treatment of intermediate and high-risk prostate cancer patients with TomoTherapy. 154 patients were treated in 8 fractions over 2-3 weeks and the median follow-up was 36 months. This approach “has shown good tolerance, little impact on quality of life, and promising disease control outcomes in an unfavorable group of prostate cancer patients.”
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical TomoTherapy for Patients with Localized Prostate Cancer.
A recent paper by Dr. Yamazaki et al from Japan compares the outcomes between 353 high-dose rate brachytherapy patients and 270 patients treated with TomoTherapy for localized prostate cancer. There were no statistically significant differences in overall survival rates among the four risk groups (low, intermediate, high, and very high), and the genitourinary toxicity was lower with TomoTherapy than with HDR brachytherapy.
Treatment Plan for Prostate Cancer
Highly-homogeneous dose. Excellent bladder and rectal sparing. Excellent small bowel sparing.